Recent studies have shown that METTL3 is highly expressed in breast cancer tissue compared to normal tissue and that silencing METTL3 could lead to a decrease in proliferation, increased apoptosis, and thereby inhibit tumor growth in vivo and in vitro. Here, METTL3 is linked to breast carcinoma.